CCND1 and cancer: Inhibition of p38 MAPK during this transition lead to a downregulation of cyclin D1 levels, slowing the conversion from G1 to S phase, thereby impeding cancer cell cycle progression and reducing cancer incidence (Lavoie et al., 1996).